Trademark Overview
On Wednesday, March 19, 2025, a trademark application was filed for OLIGOCREATOR with the United States Patent and Trademark Office. The USPTO has given the OLIGOCREATOR trademark a serial number of 79426139. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, June 19, 2025. This trademark is owned by Secarna Pharmaceuticals GmbH & Co. KG. The OLIGOCREATOR trademark is filed in the Personal, Legal & Social Services, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Licensing of industrial property rights arising from scientific research services in the field of biochemistry [excluding the field of cell culture products], nucleic acids and bioinformatics, in particular molecular biology techniques, especially antisense techniques; licensing of industrial property rights arising from the design of pharmaceutical active ingredients by means of the aforementioned processes and techniques, including the use of bioinformatics techniques; licensing of industrial property rights arising from the development of pharmaceutical products by means of the aforementioned processes and techniques, including the use of bioinformatics techniques, including the performance of associated testing and diagnostic procedures; licensing of industrial property rights arising from bioinformatic services for the pharmaceutical and biotechnological industry; licensing of industrial property rights arising from the services for evaluating the efficacy and safety of pharmaceut...
Consultancy services to third parties in the field of biochemistry and nucleic acids and bioinformatics, including antisense technology, in relation to the development of pharmaceutical products; consultancy services to third parties in relation to the evaluation of safety and efficacy of pharmaceuticals.
Scientific research services in the field of biochemistry [excluding the field of cell culture products], nucleic acids and bioinformatics, in particular molecular biology techniques, especially antisense techniques; design of pharmaceutical active ingredients by means of the aforementioned processes and techniques, including the use of bioinformatics techniques; development of pharmaceutical products by means of the aforementioned processes and techniques, including the use of bioinformatics techniques, including the performance of associated testing and diagnostic procedures; bioinformatic services for the pharmaceutical and biotechnological industry; services for evaluating the efficacy and safety of pharmaceutical products.
